FY2025 EPS Estimates for PTCT Decreased by Cantor Fitzgerald

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of PTC Therapeutics in a research note issued to investors on Monday, February 3rd. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of ($3.26) per share for the year, down from their prior forecast of ($2.84). Cantor Fitzgerald has a “Overweight” rating and a $113.00 price objective on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.56) per share.

Other research analysts have also issued research reports about the stock. Raymond James initiated coverage on shares of PTC Therapeutics in a research report on Thursday, October 10th. They set a “market perform” rating for the company. Royal Bank of Canada upgraded shares of PTC Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $39.00 to $63.00 in a report on Tuesday, December 3rd. Wells Fargo & Company boosted their price objective on shares of PTC Therapeutics from $56.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, November 26th. StockNews.com downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, The Goldman Sachs Group boosted their price objective on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $57.85.

PTC Therapeutics Price Performance

PTC Therapeutics stock opened at $49.38 on Wednesday. PTC Therapeutics has a fifty-two week low of $23.58 and a fifty-two week high of $54.16. The firm has a fifty day moving average price of $46.14 and a two-hundred day moving average price of $40.05.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.15. The firm had revenue of $196.79 million for the quarter, compared to analyst estimates of $173.51 million. During the same period in the prior year, the firm earned ($1.76) EPS.

Hedge Funds Weigh In On PTC Therapeutics

A number of large investors have recently modified their holdings of PTCT. Venturi Wealth Management LLC acquired a new position in shares of PTC Therapeutics during the fourth quarter worth approximately $68,000. R Squared Ltd acquired a new position in shares of PTC Therapeutics during the fourth quarter worth approximately $79,000. KBC Group NV lifted its holdings in PTC Therapeutics by 29.2% in the third quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 504 shares during the period. CWM LLC lifted its holdings in PTC Therapeutics by 354.7% in the third quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 2,096 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in PTC Therapeutics by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 492 shares during the period.

Insiders Place Their Bets

In other PTC Therapeutics news, CAO Christine Marie Utter sold 17,800 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $51.77, for a total transaction of $921,506.00. Following the sale, the chief accounting officer now directly owns 52,428 shares of the company’s stock, valued at approximately $2,714,197.56. This represents a 25.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Lee Scott Golden sold 810 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $36,725.40. Following the transaction, the executive vice president now owns 79,849 shares in the company, valued at $3,620,353.66. The trade was a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 211,737 shares of company stock valued at $10,920,687. 5.50% of the stock is currently owned by insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.